Related references
Note: Only part of the references are listed.Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias
R. Tibes et al.
INVESTIGATIONAL NEW DRUGS (2015)
Phase I study of terameprocol in patients with recurrent high-grade glioma
Stuart A. Grossman et al.
NEURO-ONCOLOGY (2012)
Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small Cell Lung Carcinoma
Yunguang Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Phase I/II clinical safety studies of terameprocol vaginal ointment
Niharika Khanna et al.
GYNECOLOGIC ONCOLOGY (2007)
Tetra-O-methyl nordihydroguaiaretic acid inhibits growth and induces death of leukemia cells independent of Cdc2 and survivin
Duncan H. Mak et al.
LEUKEMIA & LYMPHOMA (2007)
Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression
CC Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
